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1 IZVLEČEK 
 
Izhodišča in namen: Histološka remisija je možen terapevtski cilj pri zdravljenju bolnikov s 
Crohnovo boleznijo (CB), vendar do danes ni določenih meril za odvzem biopsij črevesne 
sluznice. Namen naše raziskave je določiti mesto za odvzem biopsij v prisotnosti razjed pri 
CB, ki daje najvišje histopatološko točkovanje, največjo sluznično mRNK izražanje pro-
vnetnih genov in največje število vnetnih celic.  
 
Hipoteza in cilji: Naša hipoteza je, da obstajajo razlike v histopatoloških točkovanjih, 
izražanju genov in številu vnetnih celic v biopsijah črevesne sluznice na različnih razdaljah 
od razjed pri CB. 
Cilji študije so določitev mesta odvzema biopsij pri CB, pridobljenih s treh različnih razdalj 
od razjed v debelem in tankem črevesu, ki ima: 
• najvišjo histopatološko točkovanje z uporabo več točkovnikov histološke aktivnosti 
bolezni, 
• najvišjo izražanje mRNK izbranih genov, 
• največje število vnetnih celic, dokazanih imunohistokemično. 
 
Metode: V prospektivno multicentrično študijo v treh centrih smo vključili 51 bolnikov s 
histološko potrjeno diagnozo CB in z razjedami > 0,5 cm v debelem in/ali tankem črevesu. 
Biopsije smo odvzeli na treh različnih razdaljah od razjede. Histopatološko aktivnost smo 
ocenili s tremi točkovniki histološke aktivnosti bolezni. Izražanje mRNK petih pro-vnetnih 
genov smo določili s kvantitativno verižno reakcijo s polimerazo. Število vnetnih celic v 
lamini proprii smo določili z imunohistokemičnim barvanjem. Za statistično analizo smo 
uporabili modele mešanih učinkov.  
 
Rezultati: Potrdili smo hipotezo, da so prisotne razlike v histopatoloških točkovanjih, 
izražanju pro-vnetnih genov in številu MPO-pozitivnih celic v biopsijah črevesne sluznice na 
različnih razdaljah od razjede pri CB. Biopsije odvzete iz roba razjede imajo večjo 
histopatološko vnetno aktivnost, izražanje mRNK pro-vnetnih genov in število MPO-
pozitivnih celic v lamini proprii v primerjavi z biopsijami odvzetimi v bližini ulkusa tako v 
debelem kot tankem črevesju (p<0,005).  
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Zaključki: Mesto odvzema biopsije pri CB, ki doseže največjo histopatološko vnetno 
aktivnost bolezni in najvišje sluznično izražanje mRNK pro-vnetnih genov, je rob ulkusa.  
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1 ABSTRACT 
 
 
Background and aim: Histological remission is a potential therapeutic target in Crohn’s 
disease (CD) but no standards exist to guide the sampling of mucosal biopsies.  We aim to 
determine the location for biopsy procurement in the presence of ulcers which yields the 
highest histopathological score, the greatest mRNA expression of pro-inflammatory genes 
and the highest number of inflammatory cells. 
 
Hypothesis and objectives: Our hypothesis is that differences in histopathological scores, 
mucosal gene expression and number of inflammatory cells of mucosal biopsies at various 
distances from ulcers in CD exist. 
The objective of the study is to determine the location of biopsy, procured from three 
different distances from ulcers in the colon and ileum, which yields: 
• the highest histopathological scores using several indices 
• the greatest mucosal mRNA expression of selected genes  
• the highest number of inflammatory cells as detected by immunohistochemistry. 
 
Methods: This prospective multicentric study enrolled 51 patients from three centers with a 
histologically confirmed diagnosis of CD and ulcers > 0.5 cm in the colon or/and ileum. 
Biopsy specimens were obtained at three different distances from ulcers. Histopathological 
disease activity was assessed using three histological scores. mRNA expression was 
measured by quantitative polymerase chain reaction. Number of inflammatory cells was 
determined by immunohistochemical staining. Statistical analysis was performed using mixed 
effects models.   
 
Results: We confirmed our hypothesis that differences in histopathological scores, mucosal 
gene expression and number of MPO-positive cells of biopsies at various distances from 
ulcers exist. Biopsies from the edge of the ulcer yield a higher histopathological score, higher 
mRNA expression of pro-inflammatory genes and higher number of MPO-positive cells 
compared to biopsies procured next to the ulcer in the colon and ileum (p<0.005).  
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Conclusion: The location for biopsy procurement which yields the highest histopathological 
score and highest mRNA expression of pro-inflammatory genes is the ulcer edge. 
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2 BACKGROUND 
 
GENERAL BACKGROUND  
 
CROHN'S DISEASE 
 
The term inflammatory bowel disease represents a group of chronic relapsing inflammatory 
intestinal disorders and principally refers to two major categories: Crohn’s disease (CD) and 
ulcerative colitis (UC).1 In CD inflammation typically involves the whole bowel wall, whereas 
in UC it is usually confined to the mucosa. Inflammation in CD is usually patchy, discontinuous 
and segmental.2 CD can affect any part of the gastrointestinal tract from the mouth to anus and 
perianal skin area, but most commonly involves the terminal ileum and colon. In a rough 
estimation, 25% of the patients have colon involved only, 25% terminal ileum only and 50% 
have ileocolitis.1 
 
EPIDEMIOLOGY OF CROHN'S DISEASE 
 
CD occurs globally, but there are important variations in both incidence and prevalence within 
geographical regions.3,4 The highest incidence rates of CD are reported in Northern Europe 
(especially Faroe Islands) and North America.4  The highest prevalence values were found in 
Europe (CD 322 per 100000 in Germany) and North America (CD 319 per 100000 in Canada).3 
In Europe, incidence rates range up to 11.5 per 100,000 person-years for CD and prevalence of 
CD ranges from 1.5 to 213 cases per 100,000 persons. The incidence of CD continues to 
increase worldwide. In Europe, the incidence of CD increased from 1.0 per 100,000 person-
years in 1962 to 6.3 per 100,000 person-years in 2010. Importantly, incidence of CD is 
increasing especially in once low-incidence regions, such as Eastern Europe and Asia.4 
Similar trends are noticed in Slovenia. A Slovenian pediatric epidemiological study found a 
mean annual incidence of inflammatory bowel disease of 4.03 cases per 100,000 children with 
60% of cases being CD (2.42 cases per 100,000). The incidences of CD rose from 1.99 cases 
per 100,000 children between 1994 to 1999 to 2.88 cases per 100,000 children between 2000 
and 2005.5 A more recent pediatric epidemiological study confirms a high incidence of CD 
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(4.6 cases per 100,000 children) which is comparable to the reported rates from western 
Europe. Interestingly, the phenotype of disease in Slovenian children has changed from more 
benign to complicated disease behavior. Stricturing and penetrating phenotype had doubled. A 
total of 19% of children with CD required surgery.6 A recent epidemiological study in the adult 
population estimated an incidence of CD of 6.1 cases per 100,000 in the period from 2010 to 
2012 with a prevalence of 150 cases per 100,000 in 2012. Similar to the pediatric population 
an increase in the incidence of CD was found in the adult population. Median age at diagnosis 
was 34 years. One in three patients had immunosuppressive drugs, one in six had a previous 
operation.7 
 
SOCIOECONOMIC ASPECTS OF CROHN'S DISEASE 
 
CD usually affects adolescents and young adults who are at their most productive and creative 
years. Frequent relapses and symptoms of active disease, disturbing extraintestinal 
manifestations, chronic and unpredictable nature of the disease, medical and surgical 
treatments and their side effects have a huge impact on daily lives of patients with CD and 
cause significant reduction in quality of life.8 CD may affect many aspects of life, including 
bowel control, fatigue, social isolation, and a fear of developing cancer or needing surgery.9 
Depression and anxiety are more common among patients with CD than the general 
population.10 CD adversely impacts work life, resulting in reduction in working hours, 
absenteeism, and changes in career choices.9 CD is associated with a significant psychosocial 
burden and beside work affects education, social life and spare time. It was estimated that 2.5 
-3 million people in Europe are affected by inflammatory bowel disease, which carries an 
estimated direct cost of 4.6-5.6 billion Euro per year.11 However, in a study from Germany the 
direct medical costs were only 32% costs of the disease. The majority of the cost (64%) were 
due to indirect costs such as early retirement or sick leave.12 An average cost of a patient with 
CD in Germany is 1425 Euro per month12 manifesting the significant economic aspect the 
disease has on societies.  
 
ETIOPATHOGENESIS 
 
Despite intensive research in the field the etiopathogenesis of inflammatory bowel disease is 
not completely known. It is a complex and multifactorial disease which is a result of an 
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interplay between immune dysregulation, genetic predisposition, gut microbiota and 
environmental factors.13 According to the most prevalent hypothesis, inflammatory bowel 
disease is an intestinal disease which develops in genetically predisposed individuals in whom 
environmental factors trigger an exaggerated immune response to luminal antigens.14 
The role of genetics in the pathogenesis was manifested by clustering of CD patients within 
families and in some ethnical groups. Since 1980s several studies found familial aggregation 
in CD with a positive family history ranging up to 25%.15 Significantly higher concordance 
rate for CD among monozygotic than among dizygotic twin pairs strongly points to a genetic 
influence.16 CD is more common in Jews than non-Jews.17 To date more than 163 genetic loci 
are known which are associated with inflammatory bowel disease. Among them 30 are specific 
for CD and 110 are associated with both CD and UC. Many of the loci are implicated in 
pathogenesis of CD, including microbe recognition, lymphocyte activation, cytokine signaling, 
epithelial defense etc. Many IBD loci are also involved in other immune-mediated disorders 
(ankylosing spondylitis and psoriasis).18 Carriers of two alleles of NOD2/CARD15 have a 17-
times increased risk to develop CD, but with at least one allele the risk of stenosing phenotype 
and small bowel involvement increases.19 
The role of environmental factors is manifested by the fact that individuals that migrate from a 
low-incidence region to a high-incidence region for CD have an increased risk of developing 
CD, particularly among first generation children.20,21 Incidence of CD is increasing in the 
developing countries; many speculate it is due to environmental factors associated with better 
socioeconomical situation, improved hygienic conditions and changes in diet. Several theories 
of environmental causes of developing CD were postulated.21 Among the most predominant 
hypothesis is the hygiene theory which proposes that the rising incidence of immune-mediated 
diseases is attributed to a lack of exposure to enteric pathogens in childhood. This can lead to 
an increased susceptibility of an inappropriate immunologic response upon exposure to new 
antigens later in life.21 Smoking is a well-known environmental risk factor which increases the 
risk for acquiring CD.22 
Many microbes have been implicated as possible causes of inflammatory bowel disease, 
including Mycobacterium avium subspecies paratuberculosis and adherent-invasive strains of 
Escherichia coli.21 However, more probably the crucial role in the etiopathogenesis is played 
by the interaction of luminal microbiota and intestinal immune system. In inflammatory bowel 
disease, the intestinal immune system is totally disrupted.23 Due to a leaky barrier microbial 
antigens from commensals gain access to the underlying mucosal tissue. In genetically 
predisposed individuals these usually harmless antigens trigger an inflammatory response 
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because dendritic cells falsely recognize commensals as pathogens and promote differentiation 
of naive T cells into effector T cells (predominantly to Th1 in CD) and natural killer T cells. 
The proinflammatory cytokines from activated T cells stimulate macrophages (part of the 
innate immune response) to secrete numerous cytokines, including tumor necrosis factor α 
(TNFα). Inflammation attracts numerous leucocytes which enter from the systemic circulation 
and release chemokines that attract even more inflammatory cells which further increases the 
inflammatory process. Tissue damage results from the release of numerous noxious mediators 
secreted by inflammatory cells.23  
 
 
CLINICAL PRESENTATION 
 
CD may manifest very acutely with severe abdominal pain and intestinal obstruction, but more 
often it presents with long-lasting symptoms. First symptoms of CD are usually subtle and 
atypical which may postpone the correct diagnosis (diagnostic delay) and appropriate 
management. Symptoms are heterogeneous because CD can involve any part of the 
gastrointestinal tract, but mostly include abdominal pain, diarrhoea, and weight loss. Systemic 
symptoms, including fever, malaise and anorexia may be present as well.24,25 Abdominal pain 
may be sustained or intermittent and colicky. It is due to abscesses, transmural inflammation 
with peritoneal pain receptors irritation, and strictures with excitation of stretch receptors in 
the bowel wall.25 Diarrhoea and blood in the stools are less common than with UC. Because of 
catabolic state induced by inflammation, poor oral intake and inadequate intestinal absorption 
of inflamed gastrointestinal tract patients with CD may be malnourished and lose weight. A 
typical feature of CD is a stricture or stenosis which is often asymptomatic. However, when 
the intestinal luminal diameter progressively shortens strictures may cause bowel obstruction 
which manifests with colicky postprandial abdominal pain, vomiting, bloating and abdominal 
distention. If the inflammation involves the entire intestinal wall, fistulas and abscesses may 
form. Symptoms of fistulas depend on the location. If a fistula has a cutaneous opening 
drainage of pus, stool, or blood is typical. Abscesses usually manifest with abdominal or 
perianal pain, spiking fever and local tenderness.25  
In general, clinical presentation of CD is dependent on the disease location, extent, disease 
behaviour, intensity of inflammation, complications of the intestine and extraintestinal 
manifestations. For example, ileal CD typically manifests with pain in the right lower quadrant, 
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usually exacerbated by meals, whereas colonic CD with diarrhoea, rectal bleeding, and 
urgency.25 
CD primarily affects the gastrointestinal tract. However, in up to 47% it may manifest in other 
organ systems as well.26 Extraintestinal manifestations can occur in each organ system of the 
human body, but are most often involve mouth (oral ulcers), eyes (uveitis, episcleritis), skin 
(erythema nodosum, pyoderma gangrenosum) and joints (peripheral arthropathies, sacroiliitis, 
ankylosing spondylitis). Some extraintestinal manifestations can be have even a bigger impact 
on quality of life of patients than the intestinal disease. Some extraintestinal manifestations 
correlate with the intestinal disease activity and normally improve with the treatment of CD, 
whereas other have a course independent of the bowel disease activity.25,26 
 
 
DIAGNOSIS OF CROHN'S DISEASE  
 
CD is a very heterogeneous disease with a variety of phenotypes in terms of disease location, 
behavior and age of onset. Therefore, it is not surprising that no gold standard for diagnosis of 
CD exists. Diagnosis of CD is established by a non-precisely defined combination of clinical 
presentation, endoscopic appearance, radiology, histology, surgical and biochemical findings. 
According to the current ECCO guidelines genetic and serological testing is not recommended 
for the diagnosis to date.24 
In the every-day clinical practice the first line procedure to diagnose CD is ileocolonoscopy 
and biopsies from the terminal ileum as well as colonic segments. Irrespective of the findings 
at ileocolonoscopy, further diagnostic investigations are recommended to determine the disease 
location, extent and behaviour. To assess the involvement of small bowel cross-sectional 
imaging (MR-enterography and CT-enterography) and trans-abdominal ultrasound are 
recommended. Small bowel capsule endoscopy is reserved for patients with a high clinical 
suspicion for CD in the small bowel despite negative findings with endoscopy and cross-
sectional imaging.24 
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TREATMENT OF CROHN'S DISEASE  
 
In general, first line treatment of CD is medicamental with drugs of various modes of action. 
Surgical therapy is indicated in case of complications and when medicamental therapy is 
ineffective.24   
The therapeutic landscape for CD is rapidly evolving in recent years. For many years, TNF 
antagonists (infliximab and adalimumab) were the mainstay for treatment of patients with 
moderate-to-severe CD. TNF antagonist were the only available biological drug for 
inflammatory bowel disease at that time. However, recently two new classes of biological 
therapy were added to the therapeutic armamentarium of CD; the integrin antagonist 
vedolizumab and the interleukin (IL)-12/23 antagonist ustekinumab. The first janus kinase 
inhibitor tofacitinib entered the market just this year, but is to date registered only for UC. 
Moreover, several new agents with different mode of action are in the pipeline to enter the 
market for treatment of CD in the years to come, many completing phase 2 and enrolling in 
phase 3 trials.27 
In the last century, no biological therapy was available. We relied on the so-called conventional 
therapy which consists of aminosalicylates, antibiotics, local and systemic corticosteroids, 
thiopurins (azathioprin, 6-mercaptopurin), methotrexate and exclusive enteral nutrition (in 
children).24 
In general, treatment of CD consists of 2 phases. First is the induction of remission, then is the 
maintenance of remission.24 Systemic corticosteroid are very effective drugs for induction of 
remission with rates of clinical remission after 3 weeks up to 90%.28 However, use of 
corticosteroids is limited by a high incidence of numerous serious side effects (cataracts, 
osteoporosis, osteonecrosis of the femoral head, myopathy, increased susceptibility to 
infection, arterial hypertension, diabetes mellitus, sleep disturbance, adrenal insufficiency, 
acne, moon face, etc).24 Systemic steroids should be used only short-term for induction of 
remission. Besides, majority of patients have a clinical relapse after cessation of 
corticosteroids.28 Therefore, drugs for maintenance of remission are needed. Traditionally, 
immunomodulators such as thiopurines and methotrexate were used for maintenance of 
remission in CD. A Cochrane review found an odd ratio for maintenance of remission with 
thiopurines of 2.32, with a number needed to treat of 6.29 In another meta-analysis, 60% of 
patients on methotrexate maintained remission compared to 39% of placebo patients, with 4 
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patients needed to be treated to prevent a relapse.30  However, the modern treatment goal of 
mucosal healing was reached in only 17% with thiopurines31 and 11% with methotrexate.32  
First biological drugs (TNF antagonists) became available at the beginning of this century and 
proof themselves to be more effective than conventional drugs.31,32 All available biological 
drugs  are indicated for induction and maintenance of remission of CD (infliximab31,33, 
adalimumab34,35, ustekinumab36, vedolizumab37). With more effective therapeutical options 
better control of disease activity is possible, which translates into long-term remission, mucosal 
healing, improved quality of life and better prognosis of patients with CD. Despite the fact that 
biological agents interfere with the immune system of patients and supress it, their safety 
profile is satisfactory.38 With more targeted mode of action as seen with vedolizumab the safety 
profile is even superior.39  
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SPECIAL BACKGROUND  
 
TREATMENT TARGETS IN CROHN'S DISEASE 
      
Historically, the treatment goal for CD has been symptom elimination with as few side effects 
as possible, but it is now known that persistent subclinical inflammation may remain which is 
believed to lead to progressive bowel damage. This can over time lead to complications of CD, 
such as intestinal strictures, fistulae and abscesses.40 These complications often translate to loss 
of organ function and need for surgical intervention (usually bowel resection), which leads to 
disability of patients with CD.41 Up to 80% of patients require surgery at some point during the 
course of CD.42 As a result, with the introduction of more effective medical therapies over the 
last decade there is an evolution in therapeutic endpoints from clinical symptom resolution to 
more strict endpoints, such as mucosal healing.43–45 Accumulating data in the literature has 
demonstrated a correlation between endoscopic response and/or remission and decreased rates 
of clinical relapse, reduced need for hospitalisation and surgery.45–49 With this convincing pile 
of evidence it is not surprising that endoscopic remission (absence of ulceration at ileo-
colonoscopy) was proposed as a treatment target for regular clinical practice in the STRIDE 
consensus recommendations.50 However, the presence of endoscopic healing does not 
necessarily correlate with an absence of histological inflammation, since up to one-third of 
biopsies from CD patients with endoscopically-healed mucosa may demonstrate evidence of 
ongoing histological disease.51–53 With the introduction of several new medical therapies 
histologic remission is a reachable target. Histological remission has been achieved with 
several drugs, including azathioprine54, methotrexate55, and infliximab51. Additionally, more 
than 50 years ago Truelove et al already described histological endpoints in clinical trials of 
inflammatory bowel disease.56 Thus, the essential question is whether histological remission 
has any additional advantages over endoscopic remission alone for favourable long-term 
outcomes of patient with CD (prevention of disease relapse, reduced need for hospitalisation 
and surgery). Is endoscopic remission sufficient or should histological remission  additionally 
be used to define mucosal healing?52 
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HISTOLOGICAL ASSESSMENT IN CROHN'S DISEASE -  BIOPSY SAMPLING 
 
CD by definition is a segmental process that may involve any part of the gut. Consequently, as 
CD can be patchy in nature, with regions of intervening normal-appearing mucosa between 
areas of ulcerations and inflammation, it is challenging to collect endoscopic mucosal biopsies 
for histopathological assessment in a consistent and reproducible manner. The optimal biopsy 
sampling is crucial for histological assessment of disease activity in CD.52,53 Without 
standardized sampling of biopsies it is not possible to determine the potential value of 
histological evaluation in management of CD and assessment of response to therapy in clinical 
trials of CD.53,57 The attendees of the STRIDE consensus felt that to date the level of evidence 
was insufficient to recommend histologic remission as a treatment target in CD in every-day 
clinical practice.50 According to the STRIDE consensus paper, the main obstacles for 
implementation of this concept (beside a lack of a validated definition of histological 
remission) was the risk of sampling error.50 To date there is no clear guidance on biopsy 
sampling or the location for biopsy procurement in the presence of patchy CD, such as ulcers. 
In previous studies biopsies were procured according to various protocols with different 
number of biopsies at various locations. In most studies biopsies were taken from the most 
macroscopically inflamed areas.57 A lack of a standardized biopsy sampling protocol was 
obvious also in recent clinical trials for assessment of response to therapy that included 
histological disease activity assessment as an trial endpoint.58,59 In the post-hoc analysis of the 
EXTEND study, up to 10 biopsy specimens were collected (two from each segment). If areas 
of active disease were present, the samples were procured from those locations.58 In the Fitzroy 
phase two trial of filgotinib for CD, 12 biopsies were procured from the least and worst affected 
site in six intestinal segments. In segments with endoscopically normal mucosa, biopsies were 
obtained at the investigator’s discretion.59 The need for standardization of biopsy sampling can 
be noticed in the literature.53,57,60 It was suggested that proper sampling of patchy lesions could 
be improved by taking biopsies from the edge of ulcers, if present.53,60 This strategy seems 
sensible, but there are no empirical evidence to support and justify this strategy.57  
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HISTOLOGICAL REMISSION IN CROHN'S DISEASE 
 
Based on the STRIDE consensus paper, the second main reason for histological remission not 
being a treatment target is a lack of a validated definition of histological remission.50  Several 
definitions of histological remission in CD were suggested, but the most appropriate one is yet 
to be determined.50,52,61 In order to evaluate histological mucosal healing as a treatment target, 
a histological scoring index is required to objectively quantify the degree of histological 
inflammation.57  In multiple histological scoring systems for inflammatory bowel disease 
definition of remission ranged from residual inflammation with persistent architectural 
distortion, to normalization of mucosa. However, the vast majority of scoring indices generally 
accepts that histological remission means at least a lack of active mucosal inflammation caused 
by neutrophils.52 Histological disease activity scoring systems in IBD vary in histological 
features, terminology and classification of severity.52,57 To date it is not known which 
histological features are most relevant for assessment of disease activity in CD.57 The first 
histological index used in inflammatory bowel disease was described in 1956.56 Several new 
CD-specific histological scoring systems have been described since then which can be broadly 
categorized as either stepwise or numerical. Stepwise indices grade inflammation into 
categories such as mild, moderate or severe. Whereas, numerical indices assign a point score 
for each histological feature evaluated which are summed to determine the final score of 
histological disease activity.57 A recent Cochrane systematical review evaluated the 
development and operating characteristics of available numeric histological disease activity 
indices for CD. The main finding was that to date there are no fully validated histological 
scoring indices for assessment of histological disease activity in CD.57 The most widely used 
histological index in clinical studies is Global Histologic Disease Activity Score (GHAS)51,62 
which was only partly validated.57 It is a numerical instrument which allows for separate 
grading of both ileal and colonic biopsies. The GHAS consists of 8 histological features 
assessing acute and chronic inflammation, extent of inflammation and epithelial damage.51,62 
The authors of the Cochrane review concluded that the development of a validated histological 
scoring system for CD is a research priority.57 
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RNA EXPRESSION OF INFLAMMATORY GENES AND IMMUNOHISTOCHEMISTRY 
 
The STRIDE consensus suggested that other histopathological and molecular methods of 
assessing inflammatory activity should ideally be developed and titrated against 
histopathology.50 Analysing mucosal gene expression, their translation, post-translational 
modifications and proteomic expression has long been a mainstay of basic medical research 
and translational medicine. Several clinical studies have investigated the role of various 
histologic biomarkers detected by immunohistochemistry as an indicator of disease 
severity.63,64 Similarly to histopathology, no standards to guide the biopsy sampling of the 
intestine for assessment of immunohistochemistry in patients with CD are known. 
Measuring the expression of inflammatory genes from mucosal intestinal biopsies is commonly 
performed in clinical studies of patients with CD. For example, expression of some 
inflammatory cytokines from intestinal biopsies was shown to be increased not only in active 
areas of disease but also in endoscopically unaffected mucosa.65 Inflammatory genes that were 
over-expressed in the setting of active CD normalize after successful treatment.66 Gene 
expression profiles can predict response to treatment with infliximab in patients with CD.67 
However, there are no current standards to guide the sampling of the intestine for gene 
expression studies in patients with CD.68 
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3 AIM, HYPOTHESIS AND OBJECTIVES  
 
Despite the increasing importance of histological disease activity assessment and mRNA 
expression in mucosal biopsies from patients with CD, it is not known where to procure 
mucosal biopsies. In this work, we aim to determine the location for biopsy procurement in 
the presence of ulcers in patients with CD which yields the highest histopathological score, 
the greatest mucosal mRNA expression of selected pro-inflammatory genes and the highest 
number of inflammatory cells as detected by immunohistochemistry. These results will allow 
us to answer the main scientific question; where to procure mucosal biopsies in the presence 
of ulcers in CD.  
 
Our hypothesis is that there are differences in histopathological disease activity scores, 
mucosal gene expression of pro-inflammatory genes and number of inflammatory cells as 
detected by immunohistochemistry  in mucosal biopsies at various distances from ulcer edge 
in CD. 
 
The objectives of the study are:  
• To determine the location for biopsy, procured from three different distances from 
ulcers in the colon and ileum in CD, which yields the highest histopathological scores 
using several histological disease activity indices. 
• To determine the location for biopsy, procured from three different distances from 
ulcers in the colon and ileum in CD, which yields the greatest mucosal mRNA 
expression of selected genes. 
• To determine the location for biopsy, procured from three different distances from 
ulcers in the colon and ileum in CD, with the highest number of inflammatory cells in 
lamina propria as detected by immunohistochemistry. 
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4 METHODS 
 
STUDY DESIGN  
 
A prospective multi-centric cross-sectional study was performed at three centers in Slovenia 
(University Medical Centre Ljubljana, Ljubljana), Belgium (Imelda General Hospital, 
Bonheiden) and the Netherlands (Academic Medical Centre, Amsterdam) from June 2016 to 
January 2017.  
The local or national ethical committees at each of these centers approved the protocol of the 
study. The National Medical Ethics Committee of Republic of Slovenia assessed the study at 
its meeting on 17th may 2016 and decided that it is ethically acceptable and thus gave consent 
(KME 103/05/16). All patients gave a written informed consent before enrollment in the study. 
 
PARTICIPANTS 
 
We defined eligible patients as those who were 18 years of age or older (male or female); who 
had a histologically confirmed CD of the terminal ileum (L1), colon (L2), or ileocolon (L3) 
according to the Montreal classification69 prior to the study ileo-colonoscopy; who were not on 
systemic anticoagulation therapy including warfarin or novel oral anticoagulants; who were 
able to participate fully in all aspects of the clinical trial; and most importantly who had at least 
a single ulcer > 0.5 cm at the study ileo-colonoscopy. We excluded all pregnant women.   
 
PROCEDURES 
 
Before the ileo-colonoscopy, all potentially eligible patients underwent a physical examination 
with measurement of vital signs, and demographical data and medical history were collected. 
Patients with at least a single ulcer > 0.5 cm in the colon or/and (neo-)terminal ileum at ileo-
colonoscopy performed as part of routine clinical care for their CD were enrolled in the study. 
All study ileo-colonoscopies were video-recorded using a central image management system. 
Endoscopic disease activity was assessed by a single blinded central reader using the Simple 
endoscopic score for Crohn’s disease (SES-CD)70. Besides eventual procurement of biopsies 
22 
 
as part of routine care (if needed), six biopsy specimens (3 for histopathological assessment 
and immunohistochemistry, and 3 for gene expression analysis) were obtained adjacent to an 
ulcer for the purpose of the study in the following manner: two biopsies perpendicular to the 
edge of the largest ulcer present in the colon and/or (neo-) terminal ileum (referred to as 
location 1); two biopsies at a distance of 1 open forceps diameter (7-8 mm) from the edge of 
the ulcer in non-ulcerated mucosa (referred to as location 2); and two biopsies at a distance of 
3 open forceps diameters (21-24 mm) from the edge of the ulcer in non-ulcerated mucosa 
(referred to as location 3). All endoscopists performing study ileo-colonoscopies were 
instructed to measure the distance from an ulcer edge with a standard open biopsy forceps (7-
8 mm in diameter). To standardize the procedure identical biopsy forceps were provided to all 
three sites (EndoJaw Alligator Jaw-step fenestrated with needle, FB220-U, Olympus). If ulcers 
were present in both the (neo-)terminal ileum and colon, 6 biopsies adjacent to the largest ulcer 
in the (neo-)terminal ileum and 6 adjacent to the largest ulcer in the colon (total of 12 biopsies) 
were obtained. If ulcers were present only in the (neo-) terminal ileum or colon, 6 biopsies 
adjacent to the largest ulcer were obtained (total of 6 biopsies). Endoscopists were instructed 
to avoid biopsies of ulcers at the anastomosis in the setting of post-operative recurrence of CD 
(possible ischemic etiology). Correct biopsy procurement (distance from the ulcer edge) was 
confirmed by the blinded central reader. His confirmation stood as the final assessment for 
eligibility of the samples in the statistical analysis.  
All individual biopsies were collected into separate labelled tubes. Half of the biopsies planned 
for histopathology and immunohistochemistry was gently put in prefilled 10 ml 10% buffered 
formalin tubes, the residual biopsies planned for mRNA gene expression analysis were 
immersed in a 2 ml Eppendorf tubes prefilled with RNA stabilization solution (RNAlater®). 
Biopsies from all sites were shipped at room temperature to the central laboratory (Tytgat 
Institute for Liver and Intestinal Research, Amsterdam UMC, The Netherlands) within 48 
hours of collection.  
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HISTOPATHOLOGICAL ASSESSMENT  
 
After routine processing of biopsies at the central laboratory (Tytgat Institute for Liver and 
Intestinal Research, Amsterdam UMC, The Netherlands), biopsies were sectioned at 4.5 μm, 
stained with hematoxylin and eosin, and digitised. All steps involved in creating a digital 
histopathology image were routinely assessed for quality control to ensure that high quality 
images were provided for central reading. A single blinded expert gastrointestinal pathologist 
trained in the scoring of histological indices reviewed each of the digitalized histopathological 
specimens and assigned numerical scores to quantify the degree of histological activity in each 
specimen. Of the current histopathological indices developed to evaluate severity of disease 
activity the Global Histological Disease Activity Score (GHAS)62, Robarts Histopathology 
Index (RHI)71 and Nancy Histological Index (NHI)72 were used. GHAS was used because it is 
among the most comprehensive and widely used scores in patients with CD.53 The GHAS is a 
numerical histological disease activity score that assesses eight items.51 In our study a 
modification of the H subscore (number of biopsy specimens affected) of the GHAS was 
performed to use percentage of affected surface in one biopsy rather than number of biopsies 
affected. The reason for that was that as only 1 biopsy per location was available for assessment 
as opposed to multiple biopsies in the original study. The RHI is a modification of the Geboes 
Score and assesses four histological features. Scores range from zero (no disease activity) to 
33 (severe disease activity). RHI was shown to be reproducible, responsive and valid in UC.71 
NHI is a simple stepwise scoring system that assesses three items, and ranges from a grade of 
zero (absence of histological disease activity) to a grade of four (severely active disease). NHI 
was shown to be valid with good reliability and responsiveness in UC patients.72 However, 
neither RHI nor NHI have been validated in CD patients. 
 
MUCOSAL GENE EXPRESSION   
 
Biopsy samples for mRNA analysis from the RNA stabilisation solution (RNAlater®) were 
homogenised using TissueLyser LT (Qiagen). RNA was extracted from the biopsy specimens 
using the Bioline Isolate II RNA Mini Kit (GC Biotech), according to the manufacturer’s 
instructions. Total RNA concentration was measured by NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific). First strand complementary DNA was synthesised from mRNA 
using RevertAid reverse transcriptase (Fermentas, Thermo Fisher Scientific), according to the 
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manufacturer’s instructions. The expression of five genes previously shown to be significantly 
up-regulated in colonic and/or ileal mucosa of CD patients in the setting of acute inflammation 
and known to be implicated in the pathogenesis of CD was analysed: 
• IL–6, a pro-inflammatory cytokine involved in the pathogenesis of CD,68,73 
• IL–8, a potent pro-inflammatory chemokine, which both attracts and activates 
granulocytes,66,68,74 
• IL–23 (p19 + p40 subunits), a pro-inflammatory cytokine secreted by innate immune 
cells that activates Th17-type T cells and has pathogenic relevance for CD,73,75,76 
• Platelet endothelial cell adhesion molecule (PECAM-1 or CD31), which mediates 
transendothelial migration and recruitment of inflammatory cells,66,77 
•  S100A9, antimicrobial peptides which form calprotectin, a fecal biomarker in 
inflammatory bowel disease.68,78 
 
Expression levels of mRNA for the genes of interest as well as reference genes (β-actin and 
cyclophillin) were determined in duplicate by quantitative real-time reverse transcriptase PCR 
using SensiFAST SYBR® No-ROX Kit (GC-Biotech) according to the manufacturer's 
instructions on a LightCycler instrument (Roche) and gene specific primers (See Table 1 for 
primers used). Relative mRNA expression levels for the genes of interest were calculated as a 
ratio relative to the geometric mean of the endogenous reference genes (β-actin and 
cyclophillin). 
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 Table 1. Primers used for qPCR analysis. 
 
 
 
  
Marker Sense Antisense 
β-actin AATGTGGCCGAGGACTTTGA TGGCTTTTAGGATGGCAAGG 
Cyclophyllin ACGGCGAGCCCTTGG TTTCTGCTGTCTTTGGGACCT 
IL-6 AGTGAGGAACAAGCCAGAGC GTCAGGGGTGGTTATTGCAT 
IL-8 AAATTTGGGGTGGAAAGGTT TCCTGATTTCTGCAGCTCTGT 
IL-23 p19 CAGGGACAACAGTCAGTTCTGC CCTCAGGCTGCAGGAGTTG 
IL-12/23 p40 Quantitect primer assays (Qiagen) 
S100A9 Quantitect primer assays (Qiagen) 
PECAM-1 Quantitect primer assays (Qiagen) 
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IMMUNOHISTOCHEMISTRY  
 
Immunohistochemical staining was used to detect the presence of inflammatory cells in the 
biopsy specimens which are increased in the colonic and ileal mucosa during active 
inflammation in CD.  Specific monoclonal antibodies directed against CD68,60,64,65 a marker 
of monocytes/macrophages, CD3, a marker of T cells, and MPO (myeloperoxidase), a marker 
of neutrophils, but also present in monocytes/macrophages, were used. Immunohistochemical 
staining of slides containing 4.5 μm biopsy sections with antibodies against CD68 
(Dako/Agilent, M0876 mouse monoclonal αCD68 clone RPM1), CD3 (Thermo Scientific, 
RM-9107, rabbit monoclonal αCD3e clone SP7) and MPO (Dako/Agilent, A0398 rabbit 
polyclonal αMPO), was performed on a Roche Ventana Benchmark Ultra IHC autostainer 
(Roche Diagnostics Nederland BV) using a Roche Optiview DAB detection kit (Roche 
Diagnostics Nederland BV) as follows: (1) antigen retrieval for 24 minutes (CD68 and MPO) 
or 48 minutes (CD3) at 100° C in Roche CC1 buffer (pH 8.5), followed by (2) incubation with 
αCD3, αCD68, or αMPO at dilutions of 1:100, 1:200 and 1:4000, respectively for 32 minutes 
at room temperature. Counterstaining of sections with hematoxylin was performed 
automatically on the Benchmark Ultra stainer.  
 Stained slides were subsequently scanned on a Philips Intellisite Ultrafast scanner 
(Philips) at 40x magnification. Whole slide images in Philips TIFF format were converted for 
processing into standard TIFF images using the GDAL/OGR Geospatial Data Abstraction 
software Library, version 2.3.2 (Open Source Geospatial Foundation), and loaded into 
Definiens Tissue Studio 4.3.1 (Definiens AG) for brightfield analysis (0.25 µm per pixel, 40x 
magnification). Images were preprocessed to identify relevant regions of interest on each slide 
and manual correction was performed to exclude various artifacts, tissue folds, regions that 
were out of focus or exhibited poor scanning quality, completely unstained large tissue 
fragments, and regions with stained epithelial cells. Colour deconvolution was used to isolate 
the hematoxylin and DAB stain channels, and nuclei were segmented in the tissue region of 
interest using a hematoxylin stain intensity threshold of 0.05 and an average nuclear size of 30 
µm². Cell simulation was performed by growing the nuclear regions. Positive cells were 
detected using DAB intensity thresholds in the cell, where intensities less than 0.3, between 
0.3 and 0.4, and greater than 0.4 were denoted as negative, “low,” and “high” for the marker 
of interest. Thresholds were chosen to classify the cellular areas, set by visual inspection of 
multiple tissue sections with positive and negative cells present. Three thresholds 
27 
 
corresponding to more permissive (low stain intensity) to more restrictive (high stain intensity) 
were chosen. 
 Total number of marker positive cells per mm2 of analysed tissue area was calculated. 
Positive cells included those classified as both “low” and “high.” Analysed tissue area was 
determined by adding areas of the tissue and stained epithelium regions of interest. 
 
STATISTICAL ANALYSIS 
 
Since multiple biopsies were taken from each patient (possible clustering effect), the mixed 
effects model approach was chosen to adjust for within subject correlations among location (1, 
2 and 3) and segments (colon and ileum).79 This mixed effects model approach was adopted to 
analyze each of the histopathological indices (GHAS, NHI and RHI), mRNA expression levels 
of the selected genes, and number of positive inflammatory cells in the lamina propria. mRNA 
expression levels and numbers of positive inflammatory cells were analyzed on the log scale 
to account for non-normality of the data. In this model biopsy location and segment were 
treated as a fixed effect and patients were regarded as random effects. 
The least square contrasts were used to compare locations in terms of histological scorings, 
mRNA expression levels for the genes of interest, and numbers of inflammatory cells. 
Statistical significance was defined with a two-sided p value of 0.05. The corresponding 95% 
confidence intervals were used to present results.  
 
Due to the lack of relevant data in the literature, the sample size was calculated using 
Cohen’s standardized effect size (mean difference divided by standard deviation). Assuming 
a comparison of scores between any two locations within a patient with a paired t-test, a 
sample of 50 subjects (pairs) will be sufficient to detect an effect size 0.4 with 80% power at 
the 5% significant level, which was from a clinical perspective an important effect size for 
each objective to make a biopsy location recommendation. This sample size was conservative 
as the mixed effects model approach is likely to be more powerful than paired t-test. 
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5 RESULTS 
 
BASELINE CHARACTERISTICS 
 
In all three centres a total of 78 patients with CD were screened. The eligibility criteria were 
met by 51 who were enrolled in the study. The reason for all 27 screen failures was a lack of 
at least a single ulcer >0.5 cm in diameter detected on ileo-colonoscopy.  
The mean age of enrolled patients was slightly above 42 years with a mean disease duration of 
13 years. Most enrolled patients had ileocolonic disease. The mean SES-CD score of the study 
patients was 11 (standard deviation [SD] = 7.5). Biopsies were procured from the ileum in 26, 
the colon in 18, and from both segments in 7 patients.  
More details on baseline patient and disease characteristics are summarised in Table 2. 
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Table 2. Baseline patient and disease characteristics 
Characteristic  
Female gender, n (%) 25 (49) 
Mean age, years (SD) 42.2 (16.7) 
Caucasian, n (%) * 49 (96.1) 
Mean disease duration, years (SD) 13.1 (10.8) 
Disease location, n (%)   
L1 16 (31.4) 
L2 8 (15.7) 
L3 22 (43.1) 
L3 + L4  5 (9.8) 
Location from which biopsies were taken, n (%)  
Ileum 26 (51.0) 
Colon 18 (35.3) 
Both 7 (13.7) 
Current medications for CD, n (%)  
Vedolizumab 7 (13.7) 
TNF antagonists 13 (25.5) 
5-ASA 4 (7.8) 
Corticosteroids and budesonide   8 (15.7) 
Immunosuppressives (thiopurines, methotrexate) 16 (31.4) 
Ustekinumab 1 (2.0) 
Patients with previous surgeries for CD, n (%)  
Abdominal 18 (35.3) 
Perianal 8 (15.7) 
Mean SES-CD score (SD) 11.0 (7.5) 
*Data missing for 2 patients.  
Disease location: L1 ileal; L2 colonic; L3 ileocolonic; L4 upper GI tract.
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HISTOPATHOLOGICAL DISEASE ACTIVITY SCORES  
 
All histological disease activity scores were highest at the ulcer edge and significant 
decreasing trends with distance from the ulcer edge were observed in all histological disease 
activity scores (p<0.05). Same decreasing trends were found in both the ileum and the colon 
(p<0.05). 
For all histological disease activity scores comparisons significant differences in both the 
ileum and the colon were observed between the ulcer edge and locations 2 and 3 (p<0.0001). 
Significant differences in histological disease activity scores were also observed between 
locations 2 and 3 in the ileum (p<0.05). No statistically significant difference between 
locations 2 and 3 in the colon was found, but there was a trend for decreased histological 
disease activity scores in location 3 relative to location 2.  
Mean histological disease activity scores of all three histological scoring indices used (GHAS, 
RHI and NHI) according to biopsy location and segment (ileum, colon) are shown in Table 
3.  
 
 
Table 3. Mean histological disease activity scores according to biopsy location and segment. 
Location: 1, edge of largest ulcer; 2, 7-8 mm from ulcer edge; 3, 21-24 mm from ulcer edge. 
Within segment pairwise comparison with location 2, 1p<0.0001; or location 3, 2p<0.0001, 
3p<0.05. 
Values in parentheses represent 95% confidence interval (CI). 
 
 
  
Segment Colon Ileum 
Location 1 2 3 1 2 3 
GHAS 10.1 (8.5, 11.7)1,2 5.2 (3.4, 6.9) 4.2 (2.5, 5.8) 8.3 (6.9, 9.6)1,2 5.1 (3.6, 6.6)3 3.1 (1.6, 4.6) 
RHI 19.5 (14.7, 24.4)1,2 5.8 (2.6, 9.0) 4.8 (2.3, 7.4) 14.2 (10, 18.3)1,2 6.6 (3.7, 9.5)3 3.4 (1.1, 5.7) 
NHI 3.3 (2.7, 3.8)1,2 1.2 (0.7, 1.8) 0.9 (0.4, 1.4) 2.7 (2.1, 3.2)1,2 1.3 (0.8, 1.8)3 0.7 (0.3, 1.2) 
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MRNA EXPRESSION OF MUCOSAL INFLAMMATORY GENES  
 
Similar to histological disease activity scores, highest mRNA expression of pro-inflammatory 
genes in mucosal biopsies was observed at the ulcer edge with decreasing trends with distance 
from the ulcer edge (p<0.05). Same significant decreasing trends were found in both the ileum 
and the colon (p<0.05). 
For all mRNA expression levels comparisons significant differences in both the ileum and the 
colon were observed between the ulcer edge and locations 2 and 3 (p<0.005).  
Log-transformed mRNA expression levels of genes of interest (IL-6, -8, -23 [p19 and p40 
subunits], CD31 and S100A9) according to biopsy location and segment are shown in Table 
4. Relative mRNA expression levels for all genes of interest were calculated as a ratio relative 
to the geometric mean of the endogenous reference genes (β-actin and cyclophillin).  
 
 
 
 
Table 4. Log-transformed mRNA expression levels for genes of interest according to biopsy 
location and segment. 
 
Within segment pairwise comparison with location 2, 1p<0.0001, 2p<0.001; or location 3, 
3p<0.0001, 4p<0.005. 
Values in parentheses represent 95% CI. 
  
  
Segment Colon Ileum 
Location 1 2 3 1 2 3 
 IL-6 -4.3 (-4.9, -3.6)1,3 -7.1 (-7.7, -6.5) -7.2 (-7.6, -6.7) -4.9 (-5.5, -4.4)1,3 -7.3 (-7.8, -6.8) -7.6 (-8.0, -7.2) 
 IL-8 -2.6 (-3.2, -2.0)1,3 -5.3 (-5.8, -4.7)4 -5.9 (-6.4, -5.3) -2.7 (-3.2, -2.1)1,3 -5.2 (-5.7, -4.7) -5.6 (-6.1, -5.1) 
 IL-23 (p19) -5.7 (-6.1, -5.3)1,3 -6.6 (-6.9, -6.3) -6.7 (-7.0, -6.4) -5.7 (-6.0, -5.3)1,3 -6.8 (-7.0, -6.5) -6.7 (-7.0, -6.5) 
 IL-23 (p40) -8.7 (-9.2, -8.2)1,4 -9.8 (-10.2, -9.4) -9.9 (-10.3, -9.5) -8.6 (-9.0, -8.2)1,4 -9.7 (-10.1, -9.3) -9.5 (-9.9, -9.1) 
 CD31 -2.1 (-2.3, -1.8)1,3 -2.7 (-2.9, -2.5) -2.7 (-3.0, -2.5) -2.2 (-2.4, -1.9)2,3 -2.6 (-2.8, -2.4)4 -2.9 (-3.1, -2.7) 
 S100A9 -1.4 (-1.8, -0.9)1,3 -3.2 (-3.6, -2.8) -3.4 (-3.8, -3.0) -1.6 (-2.0, -1.2)1,3 -3.0 (-3.3, -2.7)4 -3.3 (-3.6, -3.0) 
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IMMUNOHISTOCHEMISTRY  
 
Number of MPO-positive cells in both ileum and colon was highest at the ulcer edge and 
differed significantly compared to locations 2 and 3 (p<0.0001). A decreasing trend was 
observed in the number of these cells with distance from the ulcer edge in both the colon and 
ileum (p<0.05). 
However, these trends were not observed for CD3+ or CD68+ cells. No differences in the 
number of CD3+ or CD68+ cells were found according to biopsy location next the ulcer 
except of significant differences for the number of CD68+ cells at the ulcer edge and location 
3 as well as between locations 2 and 3 in the ileum (p<0.05).  
Log-transformed numbers of CD3+, CD68+ and MPO-positive cells per mm2 of tissue area 
according to biopsy location and segment are shown in Table 5. 
 
 
Table 5. Log-transformed number of inflammatory cells according to biopsy location and 
segment. 
 
Within segment pairwise comparison with location 2, 1p<0.0001; or location 3, 2p<0.0001, 
3p<0.05. 
Values in parentheses represent 95% CI. 
  
Segment  Colon Ileum 
Location 1 2 3 1 2 3 
 CD3+ 7.3 (7.0, 7.7) 7.3 (7.0, 7.6) 7.1 (6.7, 7.5) 7.3 (7.0, 7.6) 7.3 (7.0, 7.6) 7.3 (7.0, 7.6) 
 CD68+ 6 (5.6, 6.4) 5.9 (5.4, 6.4) 5.9 (5.4, 6.4) 6.1 (5.8, 6.5)3 6.1 (5.7, 6.5)3 5.5 (5.1, 5.9) 
 MPO+ 6.9 (6.3,7.5)1,2 4.5 (3.7, 5.2) 3.9 (3.2, 4.6) 6.6 (6.1, 7.2)1,2 4.7 (4.0, 5.3) 4.1 (3.5, 4.6) 
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6 DISCUSSION 
 
The optimal location for biopsy procurement for assessment of histological disease activity 
in inflammatory bowel disease has to date not been defined despite the increasing importance 
of histology in clinical trials in recent years. This fact is surprising since the first study to use 
a histological disease activity index in an inflammatory bowel disease trial was published 
more than 60 years ago.56 We believe this is the first study in patients with CD to assess the 
relationship between biopsy location according to ulcerations and histological disease 
activity, mucosal mRNA expression of proinflammatory genes, and number of inflammatory 
cells which are implicated in the pathogenesis of CD. 
 
We confirmed our hypothesis that differences in histopathological disease activity scores, 
mucosal gene expression of proinflammatory genes and number of MPO-positive cells in 
mucosal biopsies at various distances from ulcer edge in CD exist. These findings were not 
consistently observed for CD3+ or CD68+ cells as detected by immunohistochemistry. 
According to our objectives, the most important finding was that biopsies collected from the 
ulcer edge in both the colon and ileum yield the highest histological disease activity scores 
(irrespective of the histological scoring index used), mRNA expression levels of 
proinflammatory genes, and number of MPO-positive cells in the lamina propria. The 
existence of a gradient of inflammation from the ulcer edge to the most distant location 
evaluated in our study (21-24 mm which corresponds to 3 open forceps diameters) was 
observed. These main findings indicate that when assessing maximal disease activity in 
patients with CD with pathohistological and molecular methods biopsies should be procured 
from the edge of the ulcer. If this is not possible due to various reasons (stenosis, looping of 
the endoscope etc.), biopsies should be procured as close to the ulcer edge as possible to 
minimise sampling error. 
 
In the last decade several new agents with different mechanisms of action have been 
introduced for treatment of inflammatory bowel disease,36,37,80 with many more in the 
pipeline.27 Besides, new treatment algorithms have been implicated in the clinical 
management of patients with CD in the past years.47,81,82 These improvements have allowed 
consideration of more rigorous endpoints beyond endoscopic mucosal healing, such as 
histological mucosal healing or histological remission.52 The premise for histological 
remission in CD is that persistent histological inflammation may confer an increased risk of 
clinical symptoms, clinical relapse, hospitalisation, resection and neoplasia. However, to date 
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there is insufficient evidence to consider histological remission as a potential treatment target 
for CD in everyday clinical practice.50 Besides, there are several challenges to be addressed 
before histological remission could be considered a treatment target, including a lack of 
validated histological disease activity indices for CD,  no determined definition of histological 
remission in CD and the risk of sampling error when procuring mucosal biopsies.50  
In order to evaluate the benefit of histologic remission as a potential treatment target in CD, 
a validated histological scoring index is required to objectively quantify the degree of 
histologic inflammation.57 However, limited data exist regarding which histologic features 
are most relevant for assessing active inflammation in CD.53  
 
Before we have designed our study, we assessed operating properties of currently existing 
histological scoring indices for evaluation of disease activity in CD to identify the most 
suitable index for our study. For that reason, we performed a Cochrane systemic review to 
evaluate the development and operating characteristics of available histologic disease activity 
indices in CD.57 Electronic searches of MEDLINE, EMBASE, PubMed, and the Cochrane 
Library databases were performed from inception to July 2016 and supplemented by manual 
reviews of bibliographies and abstracts submitted to major gastroenterology meetings 
(Digestive Disease Week, United European Gastroenterology Week, European Crohn’s and 
Colitis Organisation). Any study design that evaluated a histologic disease activity score in 
adult (> 16 years) patients with CD was considered for inclusion in the systemic review. All 
titles and abstracts of the studies identified from the search were independently reviewed by 
two authors. A full text of eventually relevant studies was reviewed for inclusion. The 
investigators of the original study were contacted as needed for any clarification. From each 
eligible study we extracted and recorded data on the number of patients enrolled in the study, 
patient characteristics (age, gender, etc.), description of histologic disease activity index 
utilized; and outcomes such as content, construct and criterion validity (the extent to which 
an instrument truly measures the outcome that it is intended to assess), responsiveness (the 
ability to detect a meaningful change in health status), intra-rater and inter-rater reliability 
(the consistency or reproducibility of an instrument), and feasibility (the ease with which an 
instrument can be utilized in a given setting).57 Histologic scoring indices can be broadly 
categorized as either stepwise or numerical. Stepwise instruments separate disease activity 
into few categories (for example: mild, moderate, and severe). On the other hand, numerical 
instruments assign a point scale to biopsy findings which can then be summed to determine 
an total score.53 In our Cochrane systemic review stepwise histological scoring indices were 
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excluded. We believe that stepwise scoring indices are easy to use, but are likely to be less 
responsive to clinically meaningful changes in disease activity.57  
 
The literature search identified 3520 publications and 4 additional publications were 
identified through other sources. After duplicates removal 2573 records were screened for 
inclusion. Of these, 102 reports were selected for full text review. Eighty-six reports were 
excluded. In total we identified 16 reports of 14 studies describing 14 different numerical 
histological indices which fulfilled the inclusion criteria.57 
 
Only one study specifically aimed to develop and validate a histological index. However, this 
Naini and Corina score is not specific to assess disease activity in CD, but rather to diagnose 
inflammatory bowel disease. None of the remaining histological disease activity indices 
identified in the systemic review (including GHAS, the most widely used index in clinical 
trials and studies) has been formally fully-validated. Besides, most validation studies were of 
poor methodological quality. The conclusion of our systemic review was that there are to date 
no available fully-validated histological scoring indices to evaluate disease activity in CD and 
that validation of existing indices or development of a new one according to currently 
accepted standards is a research priority.57 
 
Among existing histological disease activity indices for CD, the partially validated and widely 
used GHAS51,60,62 was chosen in our study to assess histological inflammation because it is 
among the most comprehensive. However, a modification to assess percentage of affected 
surface in one biopsy rather than number of biopsies affected was applied. The reason for that 
was that as only 1 biopsy per location was available for assessment of disease activity as 
opposed to multiple biopsies in the original study by D’Haens. Despite this important 
modification of the GHAS, we believe it has a minor impact on the final score. Besides, we 
decided to use two additional histological scoring indices which were recently developed and 
validated for assessment of disease activity in UC (the RHI71 and NHI72). It is important to 
stress out that neither index has been validated for assessment of disease activity in patients 
with CD. However, both CD and UC belong to inflammatory bowel disease and disease 
activity in both is defined by the degree of neutrophilic inflammation and surface injury 
(ulcers and erosions). Further studies are needed to assess operating characteristics of these 
two indices in the setting of CD. Our study may provide a preliminary basis for this research.83 
 
Another important challenge in assessment of histological disease activity is the risk of 
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sampling error when procuring mucosal biopsies. Up to now, there is no guidance on biopsy 
sampling or the location for biopsy collection in presence of ulcers. The Cochrane systemic 
review we have performed has revealed that biopsies were procured according to various 
protocols with different numbers of biopsies at various locations. In majority of cases, 
biopsies were procured from macroscopically most involved areas,57 but evidence to support 
this strategy is lacking. Our study clearly shows that biopsies from the edge of an ulcer in 
both the colon or ileum yield significantly higher histological disease activity scores than 
biopsies from non-ulcerated mucosa (p<0.0001) suggesting that the inflammatory activity in 
CD is highest at the ulcer edge. These findings could be anticipated to some degree since 
erosions/ulcerations are items included in all three histological indices used in our study and 
as such contribute considerably to the final index score. Although our study was not intended 
to determine appropriate biopsy location in non-ulcerated mucosa, we observed significantly 
higher histological disease activity scores in biopsies taken from non-ulcerated mucosa closer 
to ulcers (location 2) than in biopsies further away (location 3) in the ileum and a similar non-
significant trend was observed in the colon. However, additional studies are needed to 
determine the most appropriate biopsy location in non-ulcerated mucosa. Findings of our 
study may become the core stone to develop standardised and optimised biopsy sampling 
protocols in CD while taking into account the anatomic patchiness to reduce sampling error.  
 
In the immunohistochemistry part of our study, we confirmed the highest number of MPO-
positive cells in biopsies from the ulcer edge in both the colon and ileum and a gradient of 
MPO-positive cells from the ulcer edge to the most distant location evaluated. MPO-positive 
cells mostly represent neutrophils84,85 which are associated with active inflammation in 
inflammatory bowel disease72 and are included as items of numerical histological scoring 
indices.53,57 However, the same was not true for CD3+ (T lymphocytes)86 or CD68+ 
(macrophages/monocytes)87 cells which are also important in the pathogenesis of CD. These 
cells were not more prevalent at the edge of an ulcer. Interestingly, no consistent differences 
between various biopsy locations were observed. The reason for these results is not known 
and deserves further research.  
 
Highest mRNA expression in mucosal biopsies of selected proinflammatory genes was 
observed at the ulcer edge (p<0.005) with decreasing trends with distance from the ulcer edge 
(p<0.05) in both the ileum and the colon. Indeed, assessment of mRNA expression of selected 
genes may become an important objective tool/method for management of patient with CD 
in everyday clinical practice and clinical trials. In the STRIDE consensus, authors suggested 
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that molecular methods of assessing histological remission should be developed and titrated 
against histopathology.50 It was proven that measuring pro-inflammatory gene expression 
from mucosal biopsies during colonoscopy is a feasible and reproducible method to measure 
site-specific inflammation in CD.68 No more than 2 to 5 biopsies are needed to reduce 
sampling error to <25% for most genes. Besides, expression of some pro-inflammatory genes 
correlates with endoscopic disease activity (SES-CD).68 Over-expressed pro-inflammatory 
genes in the setting of active CD may be down-regulated or even normalised after successful 
medical treatment with infliximab66,88 and adalimumab75. Additionally, normalisation of pro-
inflammatory gene expression was shown to predict long-term remission after discontinuation 
of successful treatment with TNF antagonists.76 Even before treatment is initiated, gene 
expression profiles can predict response to infliximab in patients with CD.67   
Interestingly, it was suggested that in patients with Crohn’s colitis and rectal inflammation 
analysis of gene expression in biopsies sampled from the distal colon (rectum and descending 
colon) could be used as a proxy for more proximal disease activity, which could potentially 
lead to avoiding complete colonoscopy.68 These results are consistent with our study with no 
significant differences in expression levels of pro-inflammatory genes in colon and ileum 
(data not shown). 
  
There are several strengths and limitations to our study. To best of our knowledge, this is the 
first study in patients with CD to assess the relationship between biopsy location according to 
ulcerations and outcomes of interest. Our findings are important evidence for standardisation 
of biopsy procurement in CD, especially in presence of ulcerations and may become a 
foundation for development of standardised biopsy sampling protocols in CD with the intent 
to reduce sampling errors. Two relatively new histological scoring indices (RHI and NHI) 
were tried out for assessment of disease activity in CD for the first time. Their use supports 
further validation and assessment of their operating characteristics in this disease. The very 
robust prospective study design supports the high reliability of our results. The multi-centric 
character of our study increases the generalisability of the findings. Importantly, all study 
colonoscopies were video-recorded and a blinded central reader confirmed the correct biopsy 
procurement next to the ulcer before biopsies were included in the final statistical analyses.83  
 
The fist limitation of our study is that concomitant medications were not accounted for in the 
statistical analysis. The results for mRNA expression of certain genes could have been 
influenced by drug-specific mechanisms of action. For example, mRNA expression of IL-23 
could have been depressed by treatment with ustekinumab36, an IL-12/23 antagonist. 
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However, endoscopically active CD with at least one ulcer >0.5 cm was confirmed in all 
included patients by a blinded central reader irrespective of their treatment. Secondly, data 
from patients with post-operative recurrence of CD in the neo-terminal ileum were pooled 
with data from patients with ileal CD without previous surgery. These two settings of ileal 
CD might have different etiopathogenesis and consequently different readouts. In our study, 
we evaluated 33 ileal biopsy samples in total, of which 13 were from the neo-terminal ileum. 
In a post hoc analysis no differences were observed for any of the outcomes in biopsies 
collected from the ileum or neo-terminal ileum (data not shown). Thirdly, data for ileal and 
colonic biopsies were pooled from patients with different disease location phenotype 
according to Montreal classification. To be more precise, ileal biopsies from patients with 
ileal (L1) and ileocolonic (L3) disease and colonic biopsies from patients with colonic (L2) 
and ileocolonic (L3) disease were pooled and analysed together. However, a post hoc analysis 
did not find any statistical difference in any of the study outcomes between ileal or colonic 
biopsies collected in ileocolonic disease (L3) versus purely ileal (L1) or purely colonic (L2) 
disease (data not shown). Finally, ileocolonoscopy with biopsy collection is an invasive 
procedure which can cause complications such as bleeding and perforation. In our study, two 
to four biopsies from the edge of ulcers in active CD were safe and did not cause any 
complications. However, the safety of taking multiple (more than 2 to 4) biopsies from the 
edge of ulcers in patients with active CD was not studies and may add to the risk of the 
procedural complications.   
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7 CONCLUSION 
 
Based on the results of our study we can conclude that biopsy procurement from the edge of 
an ulcer in CD consistently yielded the highest histological disease activity scores, mRNA 
expression levels of selected proinflammatory genes and numbers of neutrophils. These 
results will contribute to standardisation of procurement of biopsy samples for 
pathohistological and molecular methods in CD and reduce sampling error. These finding 
could be used in clinical trials and everyday clinical practice. Additionally, our findings add 
important evidence for development of standardised biopsy sampling protocols in CD.  
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8 OBSEŽEN POVZETEK V SLOVENSKEM JEZIKU 
 
IZHODIŠČA 
Crohnova bolezen (CB) je napredujoča bolezen, za katero je značilno kronično vnetje 
prebavnega trakta. V preteklosti je bil cilj zdravljenja CB odpravljanje simptomov s čim manj 
stranskimi učinki. Danes je znano, da lahko sub-klinično vnetje vztraja in poveča tveganje za 
razvoj zapletov, kot so stenoze, fistule in ognojki, ki zahtevajo operativno zdravljenje. 
Posledično je prišlo do premika cilja zdravljenja pri CB od odprave kliničnih simptomov do 
zazdravljenja sluznice (angl. mucosal healing). Endoskopsko zazdravljenje sluznice, ki danes 
velja za cilj zdravljenja CB, ni nujno povezano z odsotnostjo histološkega vnetja. Do tretjina 
biopsij črevesne sluznice pri bolnikih s CB z endoskopsko zazdravljeno sluznico kaže znake 
vztrajajoče histološke aktivnosti. Ključno vprašanje je torej, ali je endoskopska zazdravljenje 
sluznice dovolj za preprečitev ponovitev bolezni in prihodnjih zapletov, ali je treba vključiti 
tudi histološko remisijo.  
 
CB je po definiciji segmentni proces, ki lahko neenakomerno prizadene črevo, kjer se 
izmenjujejo področja sluznice normalnega izgleda s področji vnetja, zato je dosleden odvzem 
biopsij za oceno histološke vnetne aktivnosti težaven. Ni jasnih smernic glede mesta odvzema 
biopsij za oceno histološke vnetne aktivnosti pri CB. V preteklih raziskavah natančno mesto 
ni bilo nikoli določeno; biopsije so običajno bile odvzete iz roba razjede, v bližini razjedenih 
območij ali naključno. Potrebo po standardizaciji odvzema biopsij je bila v literaturi večkrat 
izpostavljena. 
 
Različni histološki markerji, ki jih določamo s pomočjo imunohistokemičnih metod, so se 
izkazali kot kriterij vnetne aktivnosti pri CB. Ni znanih standardov za odvzem/vzorčenje 
biopsij črevesne sluznice za imunohistokemično analizo pri bolnikih s CB. 
 
Meritve izraženosti vnetnih genov v biopsijah črevesne sluznice se pogosto uporabljajo v 
raziskovalne namene pri bolnikih s CB. Dokazano je bilo, da je izražanje vnetnih citokinov v 
biopsijah črevesne sluznice povečano tako v področjih aktivnega vnetja kot tudi v 
endoskopsko normalni sluznici. Vnetni geni, ki so bili prekomerno izraženi pri aktivni CB, 
so se normalizirali po uspešnem zdravljenju. Profili izražanja genov v biopsiji črevesne 
sluznice lahko napovedo odziv na zdravljenje pri bolnikih s CB. Mesto odvzema biopsij za 
določanje genskega izražanja pri bolnikih s CB ni znano.  
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NAMEN, HIPOTEZA IN CILJI 
Čeprav postaja pomen določanja histološke aktivnosti bolezni in izražanja mRNK v biopsijah 
črevesne sluznice pri bolnikih s CB vse večji, zaenkrat ni znano, kje je najprimerneje odvzeti 
biopsije. Namen naše raziskave je določiti mesto za odvzem biopsij v prisotnosti razjed pri 
bolnikih s CB, ki daje najvišje točkovanje histološke vnetne aktivnosti, največjo sluznično 
izražanje mRNK izbranih genov in največje število vnetnih celic, dokazanih 
imunohistokemično. Ti rezultati nam bodo omogočili odgovoriti na glavno znanstveno 
vprašanje; kje odvzeti biopsije črevesne sluznice pri bolnikih s CB v prisotnosti razjed. 
 
Naša hipoteza je, da obstajajo razlike v histopatoloških točkovanjih, izražanju genov in številu 
vnetnih celic v biopsijah črevesne sluznice na različnih razdaljah od razjed pri bolnikih s CB. 
Cilji študije so določitev mesta odvzema biopsij pri CB, pridobljenih s treh različnih razdalj 
od razjed v debelem in tankem črevesu, ki daje: 
• najvišjo histopatološko točkovanje z uporabo več točkovnikov histološke aktivnosti 
bolezni, 
• največje izražanje mRNK izbranih genov, 
• največje število vnetnih celic, dokazanih imunohistokemično. 
 
METODE 
ZASNOVA ŠTUDIJE IN POPULACIJA 
Izvedli smo prospektivno multi-centrično študijo v treh centrih v Sloveniji, Belgiji in na 
Nizozemskem, ki je vključila 51 bolnikov s CB. Odbori za raziskovalno dejavnost/lokalne 
etične komisije v vsakem od centrov so odobrili preiskavo. Vsi bolniki so pred vključitvijo v 
študijo dali pisno soglasje za sodelovanje v študiji. Primerne bolnike smo definirali kot osebe: 
ki so stare 18 let ali več (moški ali ženske); ki so že pred študijsko ileokolonoskopijo imeli 
histološko potrjeno diagnozo CB terminalnega ileuma (L1), kolona (L2) ali ileokolona (L3); 
ki niso na sistemski antikoagulacijski terapiji, vključno z varfarinom ali novimi peroralni 
antikoagulanti; ki so v celoti  zmožni sodelovati v vseh vidikih klinične študije;  in 
najpomembneje, ki imajo pri študijski ileokolonoskopiji najmanj eno razjedo večjo od 0,5 cm. 
Nosečnice smo izključili. 
Pred preiskavo smo vključene bolnike klinično pregledali, izmerili vitalne funkcije, zbrali 
demografske podatke in naredili natančno anamnezo. 
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POSTOPKI 
V študijo so vključeni bolniki z vsaj eno razjedo > 0,5 cm v debelem črevesu in/ali (neo-) 
terminalnem ileumu pri ileokolonoskopiji, opravljeni kot del rutinske obravnave za CB. Poleg 
morebitnih odvzemov biopsij kot dela rutinske obravnave smo za namene študije odvzeli šest 
biopsij zraven razjede (3 za histopatološko in imunohistokemično analizo, 3 za analizo 
genskega izražanja): dve biopsiji pravokotni na rob največje razjede v debelem črevesu in/ali 
(neo-) terminalnem ileumu, dve biopsiji na razdalji enih odprtih biopsijskih kleščic od roba 
razjeda (7-8 mm) v sluznici brez razjed in dve biopsiji na razdalji treh odprtih biopsijskih 
kleščic od roba  razjede (21-24 mm) v sluznici brez razjed. Če so bile razjede prisotne tako v 
(neo-)terminalnem ileumu kot v debelem črevesu, smo odvzeli 6 biopsij v bližini največje 
razjede (neo-)terminalnega ileuma in 6 v bližini največje razjede v debelem črevesu (skupaj 
12 biopsij). Če so bile razjede prisotne bodisi v (neo-) terminalnem ileumu bodisi v debelem 
črevesu, smo odvzeli 6 biopsij v bližini največje razjede (skupaj 6 biopsij). Vsem študijskim 
centrom smo priskrbeli biopsijske kleščice, da smo standardizirali postopek odvzema biopsij. 
Vse biopsije so bile ločeno zbrane v označene posodice. Polovica biopsij (za histopatologijo 
in imunohistokemijo) je bila vstavljena v prednapolnjene 10 ml posodice z 10% pufriranim 
formalinom, preostale biopsije (za analizo mRNK) so bile takoj potopljene v prednapolnjen 
posodice (10 ml) z RNA stabilizacijsko raztopino (RNAlater®). Biopsije iz vseh študijskih 
centrov so bile na sobni temperaturi odposlane do osrednjega laboratorija še istega dne. 
Napravili smo video-posnetke vseh študijskih ileo-kolonoskopij. Pregled ileo-kolonoskopij s 
strani centralnega ocenjevalca (ang. blinded central reader), ki ni imel nobenih informacij o 
bolnikih, je vključeval oceno endoskopske aktivnosti bolezni z uporabo točkovnika SES-CD 
(Simple Endoscopic Score for Crohn’s Disease) in potrditev pravilnega odvzema biopsij 
(prava razdalja od razjede). Potrditev pravilnega odvzema biopsij s strani centralnega 
ocenjevalca je predstavljala pogoj za vključitev bolnika v statistično analizo. 
            
HISTOPATOLOŠKA OCENA 
Vsak biopsijski vzorec je bil zbran v ločeni posodici. Po rutinskem procesiranju in barvanju 
vzorcev s H&E v centralnem laboratoriju (Inštitut Tytgat, Amsterdam, Nizozemska) smo 
diapozitive digitalizirali. Patolog, ki ni imel nobenih podatkov o bolnikih in endoskopiji, je 
pregledal vsakega od digitaliziranih vzorcev biopsij in določil številčni/točkovni rezultat 
histološke vnetne aktivnosti bolezni z uporabo histoloških točkovnikov. 
Od obstoječih histopatoloških točkovnikov, razvitih za oceno aktivnosti bolezni, smo 
uporabili GHAS (Global Histological Disease Activity Score), RHI (Robarts Histopathology 
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Index) in NHI (Nancy Histological Index). GHAS smo uporabili, ker je med najbolj 
celovitimi in pogosto uporabljenimi točkovniki pri bolnikih s CB. Podtočkovanje H v 
točkovniku GHAS smo prilagodili tako, da smo namesto števila prizadetih biopsij uporabili 
odstotek prizadete površine v eni biopsiji. Točkovnik RHI je modifikacija Geboesovega 
točkovnika, ki je ponovljiv (angl. reproducible), odziven (angl. responsive) in validiran pri 
bolnikih s ulceroznim kolitisom (UC). NHI je preprost sistem točkovanja, ki je validiran z 
visoko stopnjo odzivnosti in zanesljivosti (angl. reliability) pri UC. Ne RHI ne NHI sicer nista 
bila validirana pri bolnikih s CB.  
                   
ANALIZA MRNK  
Izražanje mRNK pro-vnetnih genov smo določili s kvantitativno verižno reakcijo s 
polimerazo. Analizirali smo izražanje petih genov, ki je pomembno povečano v sluznici 
debelega črevesja in ileuma pri bolnikih s CB pri akutnem vnetju. Ti geni so:  
• Interlevkin (IL)-8 (IL–8), potenten pro-vnetni kemokin, ki privablja in aktivira 
granulocite  
• PECAM-1 ali CD31 (angl. Platelet endothelial cell adhesion molecule), adhezijska 
molekula, ki posreduje transendotelijski prehod vnetnih celic  
• S100A9, antimikrobni peptid, ki tvori kalprotektin, fekalni biomarker pri kronični 
vnetni črevesni bolezni  
• IL–6, pro-vnetni citokin, vključen v patogenezo CB  
• IL–23 (podenoti p19 in p40), pro-vnetni citokin, ki aktivira T limfocite tipa-Th17 in 
je vpet v patogenezo CB  
Relativno izražanje mRNK opisanih genov je bilo izračunano kot razmerje glede na povprečje 
endogenih referenčnih genov (beta aktin in ciklofilin A). 
            
IMUNOHISTOKEMIČNA ANALIZA 
Imunohistokemično barvanje v biopsijskih vzorcih je bilo uporabljeno za detekcijo vnetnih 
celic, katerih število je povečano v sluznici debelega črevesja in ileuma pri bolnikih s CB pri 
aktivnem vnetju. Uporabili smo specifična monoklonska protitelesa proti CD68, markerju 
monocitov/makrofagov, CD3, markerju T limfocitov, in MPO (mieloperoksidazi), markerju 
nevtrofilcev.  
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STATISTIČNA ANALIZA  
Vsakemu preiskovancu je bilo odvzetih več biopsij, zato so bili podatki statistično analizirani 
z uporabo modelov mešanih učinkov (angl. mixed effects models), ki so upoštevali 
potencialne učinke grozdenja. Model mešanih učinkov je bil uporabljen za statistično analizo 
vsakega od točkovnikov histološke aktivnosti bolezni (GHAS, NHI in RHI), izražanja mRNK 
izbranih genov in števila vnetnih celic, dokazanih imunohistokemično. Nivo izražanja mRNK 
in število vnetnih celic smo analizirali na logaritemski skali, da bi upoštevali možno 
nenormalno razporeditev podatkov. V teh modelih smo mesto odvzema biopsij (lokacija 1, 2 
in 3) in segment (kolon ali ileum) obravnavali kot stalni učinek (angl. fixed effects), bolniki 
pa so bili obravnavani kot naključni učinek (angl. random effects).  
Za primerjavo histopatoloških točkovanj, izražanja mRNK izbranih genov in števila vnetnih 
celic smo uporabili kontraste med različnimi lokacijami. Razlike so bile opredeljene kot 
statistično pomembne pri dvostranski p vrednosti <0,05. Za predstavitev rezultatov smo 
uporabili 95-odstotni interval zaupanja.  
 
Določitev velikosti vzorca 
Zaradi pomanjkanja relevantnih podatkov v literaturi je bila velikost vzorca izračunana z 
uporabo Cohenove standardizirane velikosti učinka (povprečna razlika deljena s standardno 
deviacijo). Če primerjamo rezultate med dvema lokacijama pri preiskovancu s parnim t-
testom, je vzorec 50 oseb (parov) zadostoval za odkrivanje velikosti učinka 0,4 z 80% 
statistično močjo pri 5% stopnji statistične pomembnosti. To bi bila iz kliničnega zornega 
kota zadostna velikost učinka za vsakega od zastavljenih ciljev, da bi priporočili lokacijo 
odvzema biopsije. Izračunana velikost vzorca je konzervativna, saj je model mešanih učinkov 
verjetno statistično močnejši od parnega t-testa.  
 
REZULTATI 
Skupno smo v vseh treh centrih pregledali 78 bolnikov s CB, od katerih jih je 51 izpolnjevalo 
vse vključitvene kriterije. Razlog izključitve 27 bolnikov iz študije je bila odsotnost vsaj ene 
razjede >0,5 cm na ileokolonoskopiji. Osnovne demografske značilnosti bolnikov in 
karakteristike CB so predstavljene v tabeli 6.  
Biopsije smo pridobili iz ileuma pri 19, debelega črevesja pri 15 in iz obeh segmentov črevesja 
pri 17 bolnikih. Vsi so imeli aktivno CB s povprečno endoskopsko aktivnostjo 11 (SD = 7,5) 
po SES-CD točkovniku. 
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Tabela 6: Osnovne značilnosti bolnikov in Crohnove bolezni.  
 
Značilnost, n                                                  51 
Ženski spol, n (%) 25 (49) 
Povprečna starost, leta (SD) 42,2 (16,7) 
Povprečno trajanje bolezni, leta (SD) 13,1 (10,8) 
Lokacija bolezni, n (%)   
L1 16 (31,4) 
L2 8 (15,7) 
L3 22 (43,1) 
L3 + L4  5 (9,8) 
Lokacija odvzema biopsij, n (%)  
Ileum 19 (37,3) 
Kolon 15 (29,4) 
Oba segmenta 17 (33,3) 
Zdavilo za CB, n (%)  
Vedolizumab 7 (13,7) 
TNF antagonisti 13 (25,5) 
5-aminosalicilati (mesalazin) 4 (7,8) 
Kortikosteroidi ali budezonid   8 (15,7) 
Imunosupresivi (tiopurini, metotreksat) 16 (31,4) 
Ustekinumab 1 (2,0) 
Bolniki s predhodnimi operacijami CB, n (%)  
Abdominalne operacije 18 (35,3) 
Perianalne operacije 8 (15,7) 
Povprečna endoskopska aktivnost CB - SES-CD (SD) 11.0 (7,5) 
Lokacija bolezni: L1 ilealna, L2 kolonična, L3 ileokolonična, L4 zgornja prebavila.  
 
HISTOPATOLOŠKO TOČKOVANJE  
Povprečne vrednosti histološke aktivnosti bolezni izračunane s histološkimi točkovniki 
(GHAS, RHI in NHI) glede na razdaljo od razjede in glede na segment (ileum ali kolon) so 
predstavljene v tabeli 7.  
Trend padanja histološke aktivnosti bolezni glede na oddaljenost od razjede je bil opazen tako 
v tankem kot v debelem črevesju (p<0,05), pri čemer je najvišja histološka aktivnost CB 
opažena v biopsijah, odvzetih iz roba razjede. Statistično pomembe razlike (p<0,0001) so bile 
dokazane pri vseh primerjavah med robom razjede in lokacijama 2 oz. 3 tako v ileumu kot v 
kolonu.  
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Tabela 7: Histološka aktivnost bolezni glede na lokacijo in segment. 
Parne primerjave znotraj segmenta z lokacijo 2, 1p<0,0001, ali lokacijo 3, 2p<0,0001, 3p<0,05 
Lokacija: 1, rob največje razjede; 2, 7-8 mm od roba razjede; 3, 21-24 mm od roba razjede. 
Vrednosti v oklepajih predstavljajo 95% interval zaupanja. 
  
MRNK IZRAŽANJE PRO-VNETNIH GENOV 
Logaritmično transformirani nivoji izražanja analiziranih pro-vnetnih genov glede na razdaljo 
od razjede in glede na segment (ileum ali kolon) so predstavljeni v tabeli 8. 
Podobno kot pri histopatološki aktivnosti smo opažali trend nižjega izražanja mRNK pro-
vnetnih genov glede na oddaljenost od razjede tako v tankem kot v debelem črevesju (p<0,05), 
pri čemer je bila najvišja izraženost genov v biopsijah, odvzetih iz roba razjede. Statistično 
pomembe razlike (p<0,005) so bile dokazane pri vseh primerjavah med robom razjede in 
lokacijama 2 oz. 3 tako v tankem kot v debelem črevesju.  
 
Tabela 8: Nivo izražanja (logaritmično transformiran) izbranih pro-vnetnih genov glede na 
lokacijo in segment. 
 
Parne primerjave znotraj segmenta z lokacijo 2, 1p<0,0001, 2p<0,001; ali lokacijo 3, 3p<0,0001, 
4p<0,005. Vrednosti v oklepajih predstavljajo 95% interval zaupanja. 
 
  
  
 Kolon Ileum 
Lokacija 1 2 3 1 2 3 
GHAS 10,1 (8,5, 11,7)1,2 5,2 (3.4, 6.9) 4,2 (2,5, 5,8) 8,3 (6,9, 9,6)1,2 5,1 (3,6, 6,6)3 3,1 (1,6, 4,6) 
RHI 19,5 (14,7, 24,4)1,2 5,8 (2,6, 9,0) 4,8 (2,3, 7,4) 14,2 (10, 18,3)1,2 6,6 (3,7, 9,5)3 3,4 (1,1, 5,7) 
NHI 3,3 (2,7, 3,8)1,2 1,2 (0,7, 1,8) 0,9 (0,4, 1,4) 2,7 (2,1, 3,2)1,2 1,3 (0,8, 1,8)3 0,7 (0,3, 1,2) 
 Kolon Ileum 
Lokacija 1 2 3 1 2 3 
 IL-6 -4,3 (-4,9, -3,6)1,3 -7,1 (-7,7, -6,5) -7,2 (-7,6, -6,7) -4,9 (-5,5, -4,4)1,3 -7,3 (-7,8, -6,8) -7,6 (-8,0, -7,2) 
 IL-8 -2,6 (-3,2, -2,0)1,3 -5,3 (-5,8, -4,7)4 -5,9 (-6,4, -5,3) -2,7 (-3,2, -2,1)1,3 -5,2 (-5,7, -4,7) -5,6 (-6,1, -5,1) 
 IL-23 (p19) -5,7 (-6,1, -5,3)1,3 -6,6 (-6,9, -6,3) -6,7 (-7,0, -6,4) -5,7 (-6,0, -5,3)1,3 -6,8 (-7,0, -6,5) -6,7 (-7,0, -6,5) 
 IL-23 (p40) -8,7 (-9,2, -8,2)1,4 -9,8 (-10,2, -9,4) -9,9 (-10,3, -9,5) -8,6 (-9,0, -8,2)1,4 -9,7 (-10,1, -9,3) -9,5 (-9,9, -9,1) 
 CD31 -2,1 (-2,3, -1,8)1,3 -2,7 (-2,9, -2,5) -2,7 (-3,0, -2,5) -2,2 (-2,4, -1,9)2,3 -2,6 (-2,8, -2,4)4 -2,9 (-3,1, -2,7) 
 S100A9 -1,4 (-1,8, -0,9)1,3 -3,2 (-3,6, -2,8) -3,4 (-3,8, -3,0) -1,6 (-2,0, -1,2)1,3 -3,0 (-3,3, -2,7)4 -3,3 (-3,6, -3,0) 
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IMUNOHISTOKEMIČNA ANALIZA 
Logaritmično transformirana števila CD3+, CD68+ in MPO-pozitivnih celic na mm2 glede 
na razdaljo od razjede in glede na segment (ileum ali kolon) so prikazana v tabeli 9. 
Opažali smo gradient števila MPO-pozitivnih celic glede na oddaljenost od razjede tako v 
tankem kot v debelem črevesju (p<0,05). Število MPO-pozitivnih celic (nevtrofilci) je bilo 
najvišje na robu razjede in se je pomembno razlikovalo od lokacije 2 in 3 (p<0,0001) tako v 
tankem kot v debelem črevesju. Slednje ne velja za CD3+ in CD68+-pozitivne celice.  
 
Tabela 9: Logaritmično transformirano število CD3+, CD68+ in MPO-pozitivnih celic na 
mm2 glede na lokacijo in segment. 
 
Parne primerjave znotraj segmenta z lokacijo 2, 1p<0,0001, ali lokacijo 3, 2p<0,0001, 3p<0,05. 
Vrednosti v oklepajih predstavljajo 95% interval zaupanja. 
 
 
ZAKLJUČKI 
Gre za prvo študijo, ki je ocenjevala razmerje med mestom odvzema biopsije glede na razjedo 
in histološko aktivnostjo bolezni, nivojem izražanja pro-vnetnih genov ter številom vnetnih 
celic pri CB. Slednje je presenetljivo, saj so prve točkovnike histološke aktivnosti kronične 
vnetne črevesne bolezni opisovali že pred več kot 60 leti.  
Potrdili smo hipotezo, da obstajajo razlike v histološki vnetni aktivnosti, izražanju izbranih 
genov in številu MPO-pozitivnih celic (predstavljajo v glavnem nevtrofilce) v biopsijah 
črevesne sluznice na različnih razdaljah od razjede pri bolnikih s CB. 
Naša glavna ugotovitev je, da biopsije odvzete iz roba razjede tako v debelem črevesju kot 
ileumu dosežejo največjo histopatološko vnetno aktivnost bolezni, največje sluznično 
izražanje mRNK pro-vnetnih genov in največje število MPO-pozitivnih celic v lamini proprii. 
Obstaja gradient vnetja od roba razjede proti najbolj oddeljenemu mestu ocenjevanja biopsij 
(21-24 mm). MPO-pozitivne celice predstavljajo nevtrofilce, ki so povezani z aktivnim 
vnetjem pri kronični vnetni črevesni bolezni. Podobnega trenda pri CD3+ (T limfociti) in 
 Kolon Ileum 
Lokacija 1 2 3 1 2 3 
 CD3+ 7,3 (7,0, 7,7) 7,3 (7,0, 7,6) 7,1 (6,7, 7,5) 7,3 (7,0, 7,6) 7,3 (7,0, 7,6) 7,3 (7,0, 7,6) 
 CD68+ 6 (5,6, 6,4) 5,9 (5,4, 6,4) 5,9 (5,4, 6,4) 6,1 (5,8, 6,5)3 6,1 (5,7, 6,5)3 5,5 (5,1, 5,9) 
 MPO+ 6,9 (6,3,7,5)1,2 4,5 (3,7, 5,2) 3,9 (3,2, 4,6) 6,6 (6,1, 7,2)1,2 4,7 (4,0, 5,3) 4,1 (3,5, 4,6) 
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CD68+ (makrofagi/monociti)-pozitivnih celicah nismo opažali, saj med biopsijami med 
različnimi lokacijami ni bilo pomembnih razlik v številu teh celic.  
Naše ugotovitve bodo prispevale k poenotenju odvzema biopsij za analizo s patohistološkimi 
in molekularnimi metodami pri bolnikih s CB, kar bo vodilo v zmanjšanje napak zaradi 
vzorčenja biopsij. Naše ugotovitve bodo uporabne tako v kliničnih študijah kot v vsakodnevni 
klinični praksi.  
Menimo, da bodo naše ugotovitve osnova za standardizacijo in optimizacijo protokolov 
odvzema biopsij pri CB. Slednje bi lahko pospešilo vključitev histoloških ciljev in ciljev 
translacijske medicine v klinične študije in vsakodnevno klinično prakso.   
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